Heart rate reduction via selective 'funny' channel blockers

Current Opinion in Pharmacology

Volumn 7, Issue 2, 2007, Pages 208-213

  Bucchi, Annalisa ^a,b   Barbuti, Andrea ^a   Baruscotti, Mirko ^a   DiFrancesco, Dario ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (N ETHYL N PHENYLAMINO) 1,2 DIMETHYL 6 (METHYLAMINO)PYRIMIDINIUM CHLORIDE; ALINIDINE; ANTIARRHYTHMIC AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CILOBRADINE; DK AH 26; FALIPAMIL; INWARDLY RECTIFYING POTASSIUM CHANNEL; IVABRADINE; POTASSIUM; SODIUM CHANNEL; UNCLASSIFIED DRUG; ZATEBRADINE;

BRADYCARDIA; CALCIUM CURRENT; CARDIOVASCULAR FUNCTION; CHANNEL GATING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIASTOLE; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG SELECTIVITY; GUINEA PIG; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HEART MUSCLE CONDUCTION SYSTEM; HEART MUSCLE FIBER MEMBRANE STEADY POTENTIAL; HEART RATE; HUMAN; INHIBITION KINETICS; ISOLATED HEART; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; RABBIT; REVIEW; SINUS NODE; STABLE ANGINA PECTORIS; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER;

ANGINA PECTORIS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BENZAZEPINES; CORONARY ARTERIOSCLEROSIS; DRUG DELIVERY SYSTEMS; HEART RATE; HUMANS; ION CHANNEL GATING; ION CHANNELS; SINOATRIAL NODE;

EID: 33947141999     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.09.005     Document Type: Review

References (45)

1. DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Annu Rev Physiol 55 (1993) 455-472
2. Accili E.A., Proenza C., Baruscotti M., and DiFrancesco D. From funny current to HCN channels: 20 years of excitation. News Physiol Sci 17 (2002) 32-37
3. Baruscotti M., Bucchi A., and DiFrancesco D. Physiology and pharmacology of the cardiac pacemaker ("funny") current. Pharmacol Ther 107 (2005) 59-79
4. f. Origins and developments. Prog Biophys Mol Biol 46 (1985) 163-183
5. DiFrancesco D. The contribution of the 'pacemaker' current (if) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J Physiol 434 (1991) 23-40
6. DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res 53 (2006) 399-406
7. DiFrancesco D. Serious workings of the funny current. Prog Biophys Mol Biol 90 (2006) 13-25
8. Cerbai E., Barbieri M., and Mugelli A. Characterization of the hyperpolarization-activated current, If, in ventricular myocytes isolated from hypertensive rats. J Physiol 481 (1994) 585-591
9. Cerbai E., Pino R., Porciatti F., Sani G., Toscano M., Maccherini M., Giunti G., and Mugelli A. Characterization of the hyperpolarization-activated current, If, in ventricular myocytes from human failing heart. Circulation 95 (1997) 568-571
10. Robinson R.B., Yu H., Chang F., and Cohen I.S. Developmental change in the voltage-dependence of the pacemaker current, if, in rat ventricle cells. Pflugers Arch 433 (1997) 533-535
11. Ludwig A., Zong X., Jeglitsch M., Hofmann F., and Biel M. A family of hyperpolarization-activated mammalian cation channels. Nature 393 (1998) 587-591
12. Shi W., Wymore R., Yu H., Wu J., Wymore R.T., Pan Z., Robinson R.B., Dixon J.E., McKinnon D., and Cohen I.S. Distribution and prevalence of hyperpolarization-activated cation channel (HCN) mRNA expression in cardiac tissues. Circ Res 85 (1999) e1-e6
13. Moosmang S., Stieber J., Zong X., Biel M., Hofmann F., and Ludwig A. Cellular expression and functional characterization of four hyperpolarization-activated pacemaker channels in cardiac and neuronal tissues. Eur J Biochem 268 (2001) 1646-1652
14. f. J Biol Chem 276 (2001) 29233-29241
15. Qu J., Barbuti A., Protas L., Santoro B., Cohen I.S., and Robinson R.B. HCN2 overexpression in newborn and adult ventricular myocytes: distinct effects on gating and excitability. Circ Res 89 (2001) E8-E14
16. Fernandez-Velasco M., Goren N., Benito G., Blanco-Rivero J., Bosca L., and Delgado C. Regional distribution of hyperpolarization-activated current (If) and hyperpolarization-activated cyclic nucleotide-gated channel mRNA expression in ventricular cells from control and hypertrophied rat hearts. J Physiol 553 (2003) 395-405
17. Zicha S., Fernandez-Velasco M., Lonardo G., L'Heureux N., and Nattel S. Sinus node dysfunction and hyperpolarization-activated (HCN) channel subunit remodeling in a canine heart failure model. Cardiovasc Res 66 (2005) 472-481
18. Er F., Larbig R., Ludwig A., Biel M., Hofmann F., Beuckelmann D.J., and Hoppe U.C. Dominant-negative suppression of HCN channels markedly reduces the native pacemaker current If and undermines spontaneous beating of neonatal cardiomyocytes. Circulation 107 (2003) 485-489
19. Milanesi R., Baruscotti M., Gnecchi-Ruscone T., and DiFrancesco D. Familial sinus bradycardia associated with a mutation in the cardiac pacemaker channel. N Engl J Med 354 (2006) 151-157. In a large Italian family with asymptomatic bradycardia, the authors found that the bradycardic phenotype is tightly associated with a single-point mutation of the HCN4 pacemaker channel. Mutated channels activate at more negative voltages than do wild-type channels, which explains the heart rate-slowing effect of the mutation. This is the first report of a HCN channel mutation specifically affecting heart rate.
20. Bois P., Bescond J., Renaudon B., and Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 118 (1996) 1051-1057
21. f inhibition, while not discarding possible effects on other currents.
22. Snyders D.J., and Van Bogaert P.-P. Alinidine modifies the pacemaker current in sheep Purkinje fibers. Pflugers Arch 410 (1987) 83-91
23. Satoh H., and Hashimoto K. Electrophysiological study of alinidine in voltage clamped rabbit sino-atrial node cells. Eur J Pharmacol 121 (1986) 211-219
24. Van Bogaert P.-P., and Goethals M. Pharmacological influence of specific bradycardic agents on the pacemaker current of sheep cardiac Purkinje fibres. A comparison between three different molecules. Eur Heart J 8 (1987) 35-42
25. Goethals M., Raes A., and Van Bogaert P.-P. Use-dependent block of the pacemaker current If in rabbit sinoatrial node cells by zatebradine (UL-FS 49): on the mode of action of sinus node inhibitors. Circulation 88 (1993) 2389-2401
26. Van Bogaert P.P., and Pittoors F. Use-dependent blockade of cardiac pacemaker current (If) by cilobradine and zatebradine. Eur J Pharmacol 478 (2003) 161-171
27. DiFrancesco D. Some properties of the UL-FS 49 block of the hyperpolarization- activated current (If) in sino-atrial node myocytes. Pflugers Arch 427 (1994) 64-70
28. Satoh T.O., and Yamada M. Multiple inhibitory effects of zatebradine (UL-FS 49) on the electrophysiological properties of retinal rod photoreceptors. Pflugers Arch 443 (2002) 532-540
29. Gargini C., Demontis G.C., Bisti S., and Cervetto L. Effects of blocking the hyperpolarization-activated current (I(h)) on the cat electroretinogram. Vision Res 39 (1999) 1767-1774
30. Hu K., Naumann A., Fraccarollo D., Gaudron P., Kaden J.J., Neubauer S., and Ertl G. Heart rate reduction by zatebradine reduces infarct size and mortality but promotes remodeling in rats with experimental myocardial infarction. Am J Physiol Heart Circ Physiol 286 (2004) H1281-H1288
31. Schmitz-Spanke S., Granetzny A., Stoffels B., Pomblum V.J., Gams E., and Schipke J.D. Effects of a bradycardic agent on postischemic cardiac recovery in rabbits. J Physiol Pharmacol 55 (2004) 705-712
32. Marshall P.W., Rouse W., Briggs I., Hargreaves R.B., Mills S.D., and McLoughlin B.J. ICI D7288, a novel sinoatrial node modulator. J Cardiovasc Pharmacol 21 (1993) 902-906
33. Briggs I., and Heapy C.G. Actions of ICI D7288 on sino-atrial node cellular electrophysiology: action potentials. Br J Pharmacol 107 (1992) 382P
34. BoSmith R.E., Briggs I., and Sturgess N.C. Inhibitory actions of ZENECA ZD7288 on whole-cell hyperpolarization activated inward current (If) in guinea-pig dissociated sinoatrial node cells. Br J Pharmacol 110 (1993) 343-349
35. Harris N.C., and Constanti A. Mechanism of block by ZD 7288 of the hyperpolarization-activated inward rectifying current in guinea pig substantia nigra neurons in vitro. J Neurophysiol 74 (1995) 2366-2378
36. Gasparini S., and DiFrancesco D. Action of the hyperpolarization-activated current (Ih) blocker ZD 7288 in hippocampal CA1 neurons. Pflugers Arch 435 (1997) 99-106
37. Thollon C., Cambarrat C., Vian J., Prost J.-F., Peglion J.L., and Vilaine J.P. Electrophysiological effects of S 16257 a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol 112 (1994) 37-42
38. Bucchi A., Baruscotti M., and DiFrancesco D. Current-dependent block of rabbit sino-atrial node If channels by ivabradine. J Gen Physiol 120 (2002) 1-13
39. Borer J.S., Fox K., Jaillon P., Lerebours G., and Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107 (2003) 817-823
40. Tardif J.C., Ford I., Tendera M., Bourassa M.G., and Fox K. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26 (2005) 2529-2536. The authors compared ivabradine and atenolol in 939 patients with stable chronic angina in a double-blind non-inferiority trial, with the aim of comparing anti-anginal and anti-ischemic actions of ivabradine and the β -blocker atenolol. Non-inferiority of ivabradine was found for all exercise parameters.
41. Sulfi S., and Timmis A.D. Ivabradine - the first selective sinus node If channel inhibitor in the treatment of stable angina. Int J Clin Pract 60 (2006) 222-228
42. Vilaine J.P. The discovery of the selective If current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease. Pharmacol Res 53 (2006) 424-434. The author illustrates the steps leading to the development of ivabradine and its basic properties as a specific f-channel blocker in vitro and as an anti-ischemic drug in preclinical and clinical studies.
43. Bucchi A., Tognati A., Milanesi R., Baruscotti M., and DiFrancesco D. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. J Physiol 572 (2006) 335-346. The authors compared the blocking actions of ivabradine on HCN1 and HCN4 isoforms, and found that, although the drug acts as an 'open channel' blocker with HCN4, similar to native 'funny' channels, it acts as a 'closed channel' blocker with HCN1. This finding highlights the possibility of further exploiting these blocking differences with new drugs to accentuate HCN-isoform specificity.
44. Shin K.S., Rothberg B.S., and Yellen G. Blocker state dependence and trapping in hyperpolarization-activated cation channels: evidence for an intracellular activation gate. J Gen Physiol 117 (2001) 91-101
45. Fox K., Ferrari R., Tendera M., Steg P.G., and Ford I. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Am Heart J 152 (2006) 860-866